Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Study of tamoxifen derived perfluoroalkylated olefins in breast cancer treatment

  • Chaladaj, Wojciech
  • Arufe, M.C.
  • Lucio Martínez, Fátima
  • Fafián-Labora, J.A.
[Abstract] Estrogen-responsive breast cancer has been treated with tamoxifen since 1998, yet challenges such as limited selectivity and emerging resistance remain significant hurdles to improving therapeutic outcomes. In recent years, the incorporation of fluorine atoms in the structure of potential drugs has gained importance due to their unique properties. Perfluoroalkyl chains, known for their chemical inertness and ability to target estrogen, offer promising modifications to improve treatment efficacy. In this study, we evaluated the biological activity of 21 perfluoroalkylated tamoxifen derivatives, synthesized under mild conditions with high stereoselectivity. Seven of these compounds exhibited superior cytotoxic and selectivity activity against estrogen receptor-positive breast cancer cells (MCF-7), with IC50 values of 10.68-18.18 nM compared to 29.41 nM for 4-hydroxytamoxifen, which is used in standard therapy. Preliminary mechanism-of-action studies, supported by siRNA knockdown of ESR1 (the estrogen receptor gene), revealed that the compounds act through a similar mechanism to tamoxifen, further confirming their potential as next-generation therapeutic agents for estrogen receptor-positive breast cancer., The work was supported by MICINN (RYC2021-032567-I) funded by MCIN/AEI/10.13039/ 501100011033 and from the European Union «NextGenerationEU»/PRTR», Xunta de Galicia (ED481D-2021-020 and ED431F 2023/30), and PI23/01347 and PI20/00497, funded by Spanish National Health Institute Carlos III and co-funded by European Union and FINIBIC (RESISFERRO and ENDOPRO). J.F.-L. also thanks to the InTalent program from UDC-Inditex for the research grant. F. L-M and W. C. thank the financial support from the Polish National Science Centre (Grants 2019/35/B/ST4/00599). Funding for open access charge: Universidade da Coruña/CISUG.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Ferroptosis: an emerging strategy for managing epithelial ovarian cancer

  • Alarcón Veleiro, Carmen
  • López-Calvo, I.
  • Berjawi, Lama
  • Lucio-Gallego, Sergio
  • Mato-Basalo, Rocío
  • Quindós-Varela, María
  • Lesta-Mellid, Rocío
  • Santamarina, Isabel
  • Varela Rodríguez, Sabela
  • Fraga Mariño. María
  • Quintela, Marcos
  • Vizoso-Vázquez, Ángel
  • Arufe, M.C.
  • Fafián-Labora, J. A.
Review, [Abstract] Ferroptosis is a regulated form of cell death characterised by iron-dependent lipid peroxidation, a process intricately linked to cellular redox homeostasis. This form of cell death is induced by the accumulation of intracellular iron and the subsequent generation of reactive oxygen species (ROS), which leads to lipid peroxidation and ultimately cell death. Ferroptosis is distinct from traditional forms of cell death, such as apoptosis, and holds significant therapeutic potential, particularly in cancers harboring rat sarcoma virus (RAS) mutations, such as epithelial ovarian cancer (EOC). EOC is notoriously resistant to conventional therapies and is associated with a poor prognosis. In this review, we examine recent progress in the understanding of ferroptosis, with a particular focus on its redox biology and the complex regulatory networks involved. We also propose a novel classification system for ferroptosis modulators, grouping them into six categories (I, II, III, IV, V and VI) based on their mechanisms of action and their roles in modulating cellular redox status. By refining these categories, we aim to provide deeper insights into the role of ferroptosis in cancer biology, especially in EOC, and to identify potential therapeutic avenues. We propose that further investigation of ferroptosis in the context of redox biology could reveal novel biomarkers and therapeutic targets, offering promising strategies to overcome resistance mechanisms and improve clinical outcomes for patients with EOC and other treatment-resistant cancers., J.F.L was funded by Xunta de Galicia, grant number ED481D-2021–020, Ministerio de Ciencia e Innovación (RYC2021–032567-I), funded by MCIN/AEI/10.13039/ 501100011033 and from the European Union «NextGenerationEU»/PRTR» and the InTalent program from UDC-Inditex for the research grant and the project PI23/01347, was funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. M.C.A has been funded by the project "PI20/00497" funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. J.F.L and M.C.A are funded by Xunta de Galicia (ED431F 2023/30). J.F.L. and A.V.V. were granted with “Development of research strategic actions UDC I+D+i 2021–2022: CICA-Disrupting Projects 2021SEM-A2 (FERRSEV)”. J.F.L and M.C.A were funded by projects co-financed by FINIBIC’s Call for Development and Transfer Project Grants (RESISFERRO and ENDOPROT, respectively). C.A.V was awarded with research grant from Diputación da Coruña 2023.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Therapeutic application of mesenchymal stem cells in endometriosis

  • Varela-Pombo, Cristina
  • López-Viñas, Belén
  • Quintana Tustain, Sara
  • Guillán Maquieira, Cristina
  • Mateos, Jesús
  • Fafián-Labora, J.A.
  • Arufe, M.C.
Review, [Abstract] Endometriosis is a complex gynaecological condition that remains difficult to treat, largely because of delayed diagnosis and the wide variability of its symptoms. Mesenchymal stem cell (MSC) therapies and their derivatives, such as modified extracellular vesicles and conditioned media, have emerged as promising therapeutic strategies, acting directly on the proliferative and inflammatory processes central to the disease. Understanding current advances in experimental treatments involving stem cells and their derivatives is therefore of critical importance. A comprehensive review of MSC-based therapies in endometriosis is essential not only to consolidate existing knowledge and identify research gaps but also to evaluate the safety and efficacy of these approaches. Such a review may contribute to the development of standardised protocols and regulatory frameworks, supporting the progression from experimental models to clinical application. Ultimately, this could accelerate the development of innovative, disease-modifying therapies, offering hope to those affected by the debilitating impact of endometriosis. This review primarily explores the molecular mechanisms underlying inflammation in endometriosis and highlights experimental therapies involving MSCs and their derivatives. Particular focus is given to the therapeutic potential of MSCs in both cell- and gene-based interventions, with an emphasis on the molecular pathways involved in tissue repair and healing., JFL was funded by Xunta de Galicia, grant number ED431F-2023/30, Ministerio de Ciencia e Innovación (RYC2021-032567-I) funded by MCIN/AEI/10.13039/501100011033 and from the European Union «NextGenerationEU»/PRTR», and Project PI23/01347, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and the InTalent program from UDC-Inditex for the research grant. MCA has been funded by the project “PI20/00497” by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union and the project PDT23 by Fundación Pública Galega de Investigación Biomédica INIBIC. Funding for open access charge: Universidade da Coruña/CISUG.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Development of New Non-viral Systems for Genetic Modification of Senescent Cells

  • López-Seijas, Junquera
  • Miranda-Balbuena, Diego
  • Iglesias-Fente, Alba
  • Sacristán-Santos, Marta
  • Carballo-Pedrares, Natalia
  • Arufe, M.C.
  • Rey-Rico, Ana
  • Fafián-Labora, J.A.
[Abstract] Senescence is a process characterized by a prolonged irreversible cell-cycle arrest. The accumulation of senescent cells in tissues is related to aging and to the development of age-related diseases. Recently, gene therapy has emerged as a powerful tool for treating age-associated diseases by the transference of specific genes into the target cell population. However, the high sensitivity of senescent cells significantly precludes their genetic modification via classical viral and non-viral systems. Niosomes are self-assembled non-viral nanocarriers that exhibit important advantages due to their elevated cytocompatibility, versatility, and cost-efficiency, arising as a new alternative for genetic modification of senescent cells. In this work, we explore for the first time the use of niosomes for genetic modification of senescent umbilical cord-derived mesenchymal stem cells. We report that niosome composition greatly affected transfection efficiency; those formulations prepared in medium with sucrose and containing cholesterol as helper lipid being the most suitable to transfect senescent cells. Moreover, resulting niosome formulations exhibited a superior transfection efficiency with a markedly less cytotoxicity than the commercial reagent Lipofectamine. These findings highlight the potentiality of niosomes as effective vectors for genetic modification of senescent cells, providing new tools for the prevention and/or treatment of age-related diseases., The work was supported by MICINN (RTI2018-099389-A-100; RYC2018-025617-I; RYC2021-032567-I), Xunta de Galicia (ED431F2021/10; ED481D-2021-020), and Spanish National Health Institute Carlos III (PI20/00497). J.L.-S. acknowledges MICINN (FPU20/06176) for her pre-doctoral fellowship grant. J.F.-L. also gives thanks to the InTalent program from UDC-Inditex for the research grant., Xunta de Galicia; ED431F2021/10, Xunta de Galicia; ED481D-2021-020
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

High-Throughput Screen Detects Calcium Signaling Dysfunction in Hutchinson-Gilford Progeria Syndrome

  • Fafián-Labora, J.A.
  • Morente-López, Miriam
  • De-Toro, Javier
  • Arufe, M.C.
[Abstract] Hutchinson–Gilford progeria syndrome (HGPS) is a deadly childhood disorder, which is considered a very rare disease. It is caused by an autosomal dominant mutation on the LMNA gene, and it is characterized by accelerated aging. Human cell lines from HGPS patients and healthy parental controls were studied in parallel using next-generation sequencing (NGS) to unravel new non-previously altered molecular pathways. Nine hundred and eleven transcripts were differentially expressed when comparing healthy versus HGPS cell lines from a total of 21,872 transcripts; ITPR1, ITPR3, CACNA2D1, and CAMK2N1 stood out among them due to their links with calcium signaling, and these were validated by Western blot analysis. It was observed that the basal concentration of intracellular Ca2+ was statistically higher in HGPS cell lines compared to healthy ones. The relationship between genes involved in Ca2+ signaling and mitochondria-associated membranes (MAM) was demonstrated through cytosolic calcium handling by means of an automated fluorescent plate reading system (FlexStation 3, Molecular Devices), and apoptosis and mitochondrial ROS production were examined by means of flow cytometry analysis. Altogether, our data suggest that the Ca2+ signaling pathway is altered in HGPS at least in part due to the overproduction of reactive oxygen species (ROS). Our results unravel a new therapeutic window for the treatment of this rare disease and open new strategies to study pathologies involving both accelerated and healthy aging., This work was funded by the Spanish National Health Institute Carlos III (PI20/00497) awarded to M.C.A. Furthermore, J.A.F.-L. is funded by the Xunta de Galicia Fellowship (ED481D-2021-020), Xunta de Galicia; ED481D-2021-020
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Targeting osteoarthritis with small extracellular vesicle therapy: potential and perspectives

  • González Rodríguez, Alba
  • De-Toro, Javier
  • Jorge-Mora, Alberto
  • Fernández-Pernas, Pablo
  • Probaos Rivadulla, Carlota
  • Fraga Mariño, María
  • Fafián-Labora, J.A.
  • Arufe, M.C.
[Abstract] Osteoarthritis (OA) is a degenerative joint disease marked by inflammation, cartilage degradation, and pain, leading to a significant decline in quality of life. Recent advancements in extracellular vesicle (EV) research have introduced new therapeutic possibilities, with small extracellular vesicles (sEV) emerging as a promising strategy for OA treatment. sEV, particularly those derived from mesenchymal stem cells (MSCs), synoviocytes, chondrocytes, and induced pluripotent stem cells (iPSCs), demonstrate substantial anti-inflammatory and regenerative properties. These nanosized vesicles facilitate intercellular communication, delivering bioactive molecules that can modulate the joint microenvironment, promote chondrogenesis, and alleviate pain. Preclinical and early clinical studies indicate that sEV-based therapies may slow disease progression and enhance cartilage repair in OA patients. Despite the promising potential, challenges remain, including standardizing isolation techniques, understanding underlying mechanisms, and navigating regulatory pathways. This systematic review analyzes relevant publications published between 2019 and 2025, highlighting the therapeutic and biomarker potential of sEV in OA. Although there is substantial ongoing research into sEV and biomarkers, the fundamental understanding of OA pathogenesis remains largely unchanged, with most studies continuing to focus on established mechanisms of cartilage degradation, inflammation, and subchondral bone changes. The findings suggest that while therapeutic research into sEV is progressing, advancements in unraveling new pathophysiological mechanisms of OA are more limited. Further research is essential to optimize therapeutic protocols and establish clinical efficacy, marking sEV-based therapies as a promising but evolving approach for OA treatment., The author(s) declare that financial support was received for the research and/or publication of this article. JF-L was funded by Xunta de Galicia, grant number ED481D-2021-020, Ministerio de Ciencia e Innovación (RYC 2021-032567-I), funded by MCIN/AEI/10.13039/501100011033 and from the European Union «NextGenerationEU»/PRTR», InTalent program from UDC-Inditex for the research grant and Project PI23/01347, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. MCA has been funded by the project “PI20/00497,” funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. JF-L and MA are funded by Xunta de Galicia (ED431F 2023/30). JF-L and MA were funded by Transference Project financed FINIBIC (RESISFERRO and ENDOPROT, respectively). We also thank Fundación Pública Galega de Investigación Biomédica INIBIC (A Coruña, Spain) for granting support for the publication of open-access articles (2024/2025).